| 1. |
- Thomas, HS, et al.
(author)
-
- 2019
-
swepub:Mat__t
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
- Adam, A, et al.
(author)
-
Abstracts from Hydrocephalus 2016.
- 2017
-
In: Fluids and Barriers of the CNS. - : Springer Science and Business Media LLC. - 2045-8118. ; 14:Suppl 1
-
Journal article (peer-reviewed)
|
|
| 5. |
- Antonelli, Alexandre, 1978, et al.
(author)
-
Geological and climatic influences on mountain biodiversity
- 2018
-
In: Nature Geoscience. - : Springer Science and Business Media LLC. - 1752-0894 .- 1752-0908. ; 11:10
-
Journal article (peer-reviewed)abstract
- Mountains are key features of the Earth's surface and host a substantial proportion of the world's species. However, the links between the evolution and distribution of biodiversity and the formation of mountains remain poorly understood. Here, we integrate multiple datasets to assess the relationships between species richness in mountains, geology and climate at global and regional scales. Specifically, we analyse how erosion, relief, soil and climate relate to the geographical distribution of terrestrial tetrapods, which include amphibians, birds and mammals. We find that centres of species richness correlate with areas of high temperatures, annual rainfall and topographic relief, supporting previous studies. We unveil additional links between mountain-building processes and biodiversity: species richness correlates with erosion rates and heterogeneity of soil types, with a varying response across continents. These additional links are prominent but under-explored, and probably relate to the interplay between surface uplift, climate change and atmospheric circulation through time. They are also influenced by the location and orientation of mountain ranges in relation to air circulation patterns, and how species diversification, dispersal and refugia respond to climate change. A better understanding of biosphere-lithosphere interactions is needed to understand the patterns and evolution of mountain biodiversity across space and time.
|
|
| 6. |
- Balla, N. K., et al.
(author)
-
Polarized Nonlinear Nanoscopy of Metal Nanostructures
- 2017
-
In: ACS Photonics. - : American Chemical Society (ACS). - 2330-4022. ; 4:2, s. 292-301
-
Journal article (peer-reviewed)abstract
- Nonlinear signals from metal nanostructures are known to be highly polarization-dependent, due to the intrinsic vectorial nature of nonlinear optical coupling. Nonlinear optical polarization responses contain important information on the near-field properties of nanostructures;, however, they remain complex to monitor and to model at the nanoscale. Polarization resolved nonlinear optical microscopy can potentially address this question; however, the recorded signals are generally averaged over the diffraction-limited size of a few hundreds of nanometers, thus, missing the spatial specificity of the nanostructure's optical response. Here we present a form of polarization resolved microscopy, named polarization nonlinear nanoscopy, which reveals subdiffraction scale vectorial variations of electromagnetic fields, even though the intensity image is diffraction-limited. We show that by exploiting, at a single subdiffraction pixel level, the information gained by the polarization-induced modulation, it is possible to spatially map the vectorial nature of plasmonic nonlinear optical interactions in nanostructures, revealing in particular surface contributions, retardation effects, and anisotropic spatial confinements.
|
|
| 7. |
|
|
| 8. |
- Hui-Yuen, JS, et al.
(author)
-
Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices
- 2015
-
In: The Journal of rheumatology. - : The Journal of Rheumatology. - 0315-162X .- 1499-2752. ; 42:12, s. 2288-2295
-
Journal article (peer-reviewed)abstract
- To evaluate the use and efficacy of belimumab in academic practices. Belimumab is a human monoclonal antibody that inhibits soluble B lymphocyte stimulator and has been approved for the treatment of adults with systemic lupus erythematosus (SLE).Methods.Invitations to participate and complete a 1-page questionnaire for each patient prescribed belimumab were sent to 16 physicians experienced in SLE phase III clinical trials. The outcome was defined as the physician’s impression of improvement in the initial manifestation(s) being treated without worsening in other organ systems.Results.Of 195 patients treated with belimumab at 10 academic centers, 96% were taking background medications for SLE at initiation of belimumab, with 74% taking corticosteroids. The main indications for initiation of belimumab were arthritis, rash, and/or worsening serologic activity, with 30% of patients unable to taper corticosteroids. Of the 120 patients taking belimumab for at least 6 months, 51% responded clinically and 67% had ≥ 25% improvement in laboratory values. While numbers are limited, black patients showed improvement at 6 months. In a subset of 39 patients with childhood-onset SLE, 65% responded favorably at 6 months, and 35% discontinued corticosteroids.Conclusion.Our data demonstrate favorable clinical and laboratory outcomes in patients with SLE at 6 months across all racial and ethnic groups, with similar improvement seen among patients with childhood-onset SLE.
|
|
| 9. |
|
|
